Media coverage about Antares Pharma (NASDAQ:ATRS) has been trending somewhat positive on Friday, AlphaOne Sentiment reports. The research group, a subsidiary of Accern, rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. AlphaOne ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Antares Pharma earned a news impact score of 0.10 on AlphaOne’s scale. AlphaOne also assigned media headlines about the specialty pharmaceutical company an impact score of 64 out of 100, meaning that recent press coverage is somewhat likely to have an impact on the company’s share price in the near term.
Separately, Raymond James Financial, Inc. began coverage on shares of Antares Pharma in a research report on Thursday. They set a “strong-buy” rating and a $4.30 price objective for the company.
Shares of Antares Pharma (NASDAQ:ATRS) traded up 3.26% during midday trading on Friday, hitting $2.85. 2,627,432 shares of the stock traded hands. Antares Pharma has a 52 week low of $0.79 and a 52 week high of $3.10. The firm has a 50-day moving average price of $2.72 and a 200-day moving average price of $2.22. The stock’s market capitalization is $442.44 million.
Antares Pharma (NASDAQ:ATRS) last issued its earnings results on Tuesday, March 14th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.01. Antares Pharma had a negative return on equity of 45.93% and a negative net margin of 53.11%. The business earned $14.20 million during the quarter, compared to analyst estimates of $12.77 million. On average, equities analysts predict that Antares Pharma will post ($0.11) earnings per share for the current fiscal year.
In other Antares Pharma news, Director Leonard S. Jacob sold 20,000 shares of the business’s stock in a transaction dated Monday, April 3rd. The stock was sold at an average price of $2.88, for a total value of $57,600.00. Following the completion of the transaction, the director now owns 238,885 shares of the company’s stock, valued at approximately $687,988.80. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Thomas J. Garrity sold 30,000 shares of the business’s stock in a transaction dated Friday, March 31st. The stock was sold at an average price of $2.91, for a total value of $87,300.00. Following the completion of the transaction, the director now directly owns 190,213 shares of the company’s stock, valued at approximately $553,519.83. The disclosure for this sale can be found here. In the last three months, insiders sold 168,762 shares of company stock valued at $496,592. 10.77% of the stock is owned by insiders.
About Antares Pharma
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.
Receive News & Ratings for Antares Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.